Opinion|Videos|December 3, 2024
Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC
This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Are there any other therapies you wish to highlight for the management of EGFR-mutated NSCLC across the various stages of disease progression?
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.
ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.
PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5